Read previous post:
Oncolytics Biotech is undervalued, says Canaccord Genuity

A major milestone for Oncolytics Biotech (TSX:ONC) is being cheered by Canaccord Genuity analyst Neil Maruoka. On Friday, Oncolytics Biotech...

Close